Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Ipsen Yönetim

Yönetim kriter kontrolleri 4/4

Ipsen's CEO'su David Loew, Jul2020 tarihinde atandı, in görev süresi 4.25 yıldır. in toplam yıllık tazminatı € 4.36M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.6% maaş ve 77.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.061% ine doğrudan sahiptir ve bu hisseler € 5.63M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 10.9 yıldır.

Anahtar bilgiler

David Loew

İcra Kurulu Başkanı

€4.4m

Toplam tazminat

CEO maaş yüzdesi	22.6%
CEO görev süresi	4.3yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	5.4yrs
Yönetim Kurulu ortalama görev süresi	10.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

David Loew'un ücretlendirmesi Ipsen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

Tazminat ve Piyasa: David 'ın toplam tazminatı ($USD 4.83M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.31M ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Loew (57 yo)

4.3yrs

Görev süresi

€4,361,753

Tazminat

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Loew	MD, CEO & Director	4.3yrs	€4.36m	0.061% € 5.9m
Aymeric Le Chatelier	Executive VP & CFO	9.9yrs	€1.02m	Veri yok
Aidan Murphy	Executive VP and Head of Technical Operations	6.8yrs	Veri yok	Veri yok
Craig Marks	Vice-President of Investor Relations	no data	Veri yok	Veri yok
Francois Garnier	Executive VP of Legal Affairs	9.8yrs	Veri yok	Veri yok
Regis Mulot	Executive VP & Chief Human Resources Officer	6.6yrs	Veri yok	Veri yok
Dominique Bery	Head of Nordics & Baltics	7.5yrs	Veri yok	Veri yok
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	4.1yrs	Veri yok	Veri yok
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	4yrs	Veri yok	Veri yok
James Levine	President of Fondation Ipsen	no data	Veri yok	Veri yok
Mari Scheiffele	Executive VP & President of International	2.9yrs	Veri yok	Veri yok
Catherine Abi-Habib	Executive VP and Head of Strategy & Transformation	2.6yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: I7G 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Loew	MD, CEO & Director	4.4yrs	€4.36m	0.061% € 5.9m
Marc M. de Garidel	Non-Executive Chairman	13.9yrs	€600.00k	0.17% € 16.1m
Margaret Liu	Independent Director	7.3yrs	€130.00k	0.00084% € 80.0k
Michèle Ollier	Director	9.4yrs	€65.00k	0.00061% € 58.1k
Karen Witts	Independent Director	2.8yrs	€115.00k	0.00061% € 58.1k
Antoine Flochel	Vice Chairman	19.2yrs	€165.00k	0.0037% € 347.7k
Henri Beaufour	Director	19.2yrs	€36.00k	0% € 0
Anne Beaufour	Director	19.2yrs	€45.00k	26.54% € 2.5b
Carol Xueref	Director	12.3yrs	€115.00k	0.00061% € 58.1k
Philippe Bonhomme	Director	12.8yrs	€95.00k	0% € 0
Piet Wigerinck	Independent Director	6.4yrs	€78.00k	0.00083% € 79.1k
Laetitia Ducroquet	Employees Representative Director	3.9yrs	Veri yok	0.0010% € 96.2k

10.9yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: I7G 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.9 yıldır).

Ipsen Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ipsen Announces Executive Changes

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

First half 2024 earnings released: EPS: €2.92 (vs €2.36 in 1H 2023)

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Upcoming dividend of €1.20 per share

Ipsen Announces Executive Changes

Dividend of €1.20 announced

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings released: EPS: €7.79 (vs €7.20 in FY 2022)

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings released: EPS: €2.36 (vs €4.63 in 1H 2022)

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings released: EPS: €7.20 (vs €7.64 in FY 2021)

Full year 2022 earnings released: EPS: €7.20 (vs €7.82 in FY 2021)

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Upcoming dividend of €1.20 per share

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

First half 2021 earnings released: EPS €3.66 (vs €2.65 in 1H 2020)

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Upcoming dividend of €1.00 per share

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Full year 2020 earnings released: EPS €6.56 (vs €0.66 loss in FY 2019)

New 90-day low: €66.15

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma

Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx®

Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

CEO Tazminat Analizi